Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim’s rival drug had mixed results in late-stage trials. Data from two late-stage trials of Boehringer’s nintedanib showed the drug improved patients’ lung function, but one trial fell short of meeting its key secondary goals of improving overall health and delaying a disease flare up. Nintedanib and InterMune’s pirfenidone are aimed at treating idiopathic pulmonary fibrosis (IPF) — an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung’s ability to absorb oxygen.
Help employers find you! Check out all the jobs and post your resume.
